Physician profile
Alfredo E Rumilla
NPI 1063594554
$753.43
in general payments reported to CMS, 2019-2025
12 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $86.48 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $200.76 | 2019-2025 | |
| Novo Nordisk INC | $152.02 | 2019 | |
| Abbott Laboratories | $107.77 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.10 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.80 | 2019 | |
| Lilly USA, LLC | $30.78 | 2020-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $26.73 | 2019 | |
| Exact Sciences Corporation | $20.82 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $15.77 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $13.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Rumilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.